UNITY 2: A STUDY OF AN INVESTIGATIONAL TREATMENT REGIMEN OF DCV+ASV+BMS-791325 IN A FIXED DOSE COMBINATION (THE DCV 3DAA (DIRECT ACTING ANTIVIRAL) REGIMEN) WITH OR WITHOUT RBV FOR 12 WEEKS FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS(HCV)GENOTYPE 1 INFECTION IN SUBJECTS WITH COMPENSATED CIRRHOSIS: